4.29

0.00% 0.00

After Hours: 4.29

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $4.29, with a volume of 1.13M. It is up +0.00% in the last 24 hours and up +5.93% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$4.29

Open:

$4.28

24h Volume:

1.13M

Relative Volume:

1.59

Market Cap:

$425.34M

Revenue:

$9.01M

Net Income/Loss:

$-99.72M

P/E Ratio:

-0.9453

EPS:

-4.5381

Net Cash Flow:

$-92.85M

1W Performance:

+2.88%

1M Performance:

+5.93%

6M Performance:

+25.81%

1Y Performance:

+46.42%

1-Day Range:

$4.19

$4.455

1-Week Range:

$4.13

$4.82

52-Week Range:

$2.45

$4.83

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1075)

Industry

Biotechnology (601)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

Twitter

@x4pharma

Next Earnings Date

2026-08-14

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	4.29	425.34M	9.01M	-99.72M	-92.85M	-4.5381
VRTX Vertex Pharmaceuticals Inc	516.44	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.97	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	856.94	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	202.00	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	356.01	40.62B	5.76B	514.49M	1.10B	4.4813

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Initiated	Guggenheim	Buy
Dec-05-25	Resumed	Stifel	Buy
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

04:43 AM

X4 Pharma chairman Craig R. sells $210,829 in shares By Investing.com - Investing.com Canada

04:43 AM

04:01 AM

X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026) - Stock Titan

04:01 AM

Aug 12, 2026

Industry Analysts Just Made A Dazzling Upgrade To Their X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Revenue Forecasts - simplywall.st

Aug 12, 2026

Aug 11, 2026

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why - Yahoo Finance

Aug 11, 2026

XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets - MarketBeat

Aug 11, 2026

Layoff Tracker: MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles - biospace.com

Aug 11, 2026

Aug 10, 2026

Earnings Update: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st

Aug 10, 2026

Equities Analysts Issue Forecasts for XFOR FY2029 Earnings - MarketBeat

Aug 10, 2026

Aug 07, 2026